Featured Story

  • Struggling Unilife extends negotiating period with Amgen over partial takeover

    Struggling injection device specialist Unilife said in an SEC filing that it needs an additional week to negotiate a deal with potential savior Amgen, which would involve the big biotech purchasing up to 19.9% of the company's stock in return for a much-needed cash infusion. If the grand alliance pans out, Amgen would also gain the preferred right of access to new drug delivery platforms and enter into a manufacturing arrangement with Unilife.

'Crystal balls' in drug delivery could be stronger than liposomes

Researchers at Philadelphia's Drexel University have developed a microscopic "crystal ball" that could someday be used for drug delivery.

Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch

Malvern, PA's Scilex Pharmaceuticals is seeking to deploy its transdermal drug delivering patch to break into the post-herpetic neuralgia market, which is led by an Endo drug that had peak sales of $1.4 billion.

Spero Therapeutics raises $30M to support its drug delivery platform targeting Gram-negative bacteria

Cambridge, MA's Spero Therapeutics has raised $30 million in Series B financing to develop its so-called Potentiator Platform to improve existing antibiotics by enabling them to pass through the cell membrane of Gram-negative bacteria.

Despite words to the contrary, Flamel's $20M acquisition is a clear drug delivery play

Flamel Technologies officials sold the $20.25 million takeover of Charlotte, NC's FSC Pediatrics as part of the company's "journey from a pure drug delivery company to a diversified specialty pharma company," but then went on to describe how each of the new products in its portfolio counts drug delivery as one of its key differentiators. Whether done purposefully or not, it just goes to show the importance of drug delivery, even to those who strive to be diversified players.

FDA says drug delivery devices need human factors validation testing

Several drug delivery devices are on a draft list of med tech that will be subject to a final guidance calling for the application of human factors and usability engineering to medical devices.


From Our Sister Sites


Mumbai-based Sun Pharmaceutical Industries wants the U.S. FDA to re-inspect its troubled Halol plant between April and June after efforts at answering complaints from a leaky ceiling that were first noted in September 2014 and some of which were highlighted in a December 2015 warning letter as still pending.  


Pfizer Consumer Healthcare announced the launch of joint health and wellness innovation program that will enable 10 med tech startups to utilize the San Francisco office of tech industry incubator Galvanize.